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Current therapeutic uses of umbilical cord blood stem cells and the promise of these cells for 
the treatment of degenerative diseases in the future have led to the establishment of cord 
blood banks in many parts of the world. Although umbilical cord blood banking raises many 
ethical and legal issues, this article focuses on the controversy created by the coexistence of 
public and private cord blood banks in many countries. Policy statements adopted by 
professional associations and advisory groups indicate that, based on the current state of 
medical evidence, childbearing women with no current or potential familial need of stem cell 
transplantation should be encouraged to donate cord blood to public banks. Collected cord 
blood that does not meet standards for transplantation should be made available for research, 
and options should be provided to parents so that they can make informed decisions 
regarding which types of research they are willing to support.  
 
 
The umbilical cord, previously considered as 
waste and discarded at birth, is a source of 
haematopoietic stem cells that can currently 
be used for the treatment of blood 
malignancies and inherited blood and 
metabolic disorders.1  
As an alternative to bone marrow transplants, 
umbilical cord blood presents certain 
advantages: it can be collected at birth, 
without pain to either mother or child; the 
number of potential donors is high; after 
collection, typing, testing and freezing can be 
quickly performed, making the stem cells 
rapidly available for shipping to any recipient. 
In addition, transplants of partial HLA2 
matches are more successful with umbilical 
cord blood cells than with bone marrow cells. 
Disadvantages include a longer time to 
engraftment for cord blood transplants 
compared to bone marrow, which can leave 
the recipient vulnerable to infections, the risk 
of transmission of a hereditary disease 
through cord blood stem cells (which would be 
undiagnosed in the donor at birth), and the 
often comparatively low stem cell count in 
collected cord blood.3 
Since the first report of successful cord blood 
transplantation in 1988, more than 6000 
transplantations have been performed 
worldwide.4 The use of umbilical cord blood 
cells is well established in children,5 but not so 
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in adults, because a unit of umbilical cord 
blood collected at delivery often does not yield 
enough cells to treat adults. Research has 
shown that the stem cells found in a unit of 
cord blood would not suffice to treat adults 
weighing more than 110 pounds. Certain 
strategies, such as cell expansion and 
transplantation of cells from multiple cords, are 
currently being developed and more 
successful cord blood transplants are being 
performed on adults participating in these 
trials.6 
In addition to blood precursor cells, umbilical 
cord blood apparently also contains stem cells 
that can differentiate into other types, such as 
cartilage, fat, hepatic, cardiac and neural 
cells,7 prompting speculation as to the 
potential use of cord blood stem cells for 
regenerative medicine. Advances in the 
expansion of cord blood stem cells may then 
solve the insufficiency problem thereby 
allowing increased transplantations to treat 
degenerative conditions in adults.8 However, 
this remains largely speculative at the present 
time. 
Current therapeutic uses of umbilical cord 
blood stem cells and the promise of these 
cells for the treatment of degenerative 
diseases in the future have led to the 
establishment of cord blood banks in many 
parts of the world.9 Although this practice 
raises questions of safety and other ethical, 
legal and social issues, the present discussion 
will focus on certain aspects of the 
coexistence of public and private banks. 
Public and Private Banks. Public banks make 
cells available to anyone who might need 
them on the basis of a good HLA match. To 
fulfill this function, these banks store large 
numbers of samples of transplant-suitable 
cord blood stem cells with the goal of 
maximizing the chances of finding a donor 
match for any unrelated recipient. Their aim is 
to provide equitable access to stored cord 
blood stem cells, while not limiting 
participation to families who have the financial 
means. Public banks in the United States 
generally charge between $15,000 and 
$35,000 per unit of cord blood provided for 
transplantation, a cost usually covered by 
health insurance.10 By one count, there are 28 
public cord blood banks in the United States;11 
there are two such banks in Canada. One 
estimate put the world supply of cord blood 
units in public banks (in 2004) at between 
175,000 and 200,000.12 
In contrast, private banks will process and 
store umbilical cord blood for a fee, reserving 
it for the use of the "donor" child or family 
rather than making it available to all who may 
need it. The purpose of these banks is to allow 
families that can afford the preparation 
(between $1000-2000) and annual storage 
(between $100-200) fees access to cord blood 
for eventual use.13 Recent reports show that 
well-known figures, such as football stars and 
royalty,14 who have had recourse to these 
banks have contributed to publicize this 
practice and highlighted the promises held out 
to buyers, such as the reported assertion by 
one football player that these cells would 
provide insurance against tendon or cartilage 
problems.15 One organization has identified 41 
private banks in North America, 42 in Europe 
and 28 in Asia.16 No reliable statistics are 
available as to the number of units in private 
banks. 
A recent initiative, the Virgin Health Bank, 
proposes a "dual" approach to cord blood 
banking, dividing the collected umbilical cord 
blood between a public bank (80% of the 
collected blood), where the cells will be 
available for anyone's use, and a private bank 
(20% of the collected sample), where the 
remaining cells will be available to the "donor" 
child or family in case of need.17 Parents 
choosing this option will pay fees comparable 
to those of other private banks.18 It should be 
noted that currently unavailable cell expansion 
technology will be required to obtain sufficient 
numbers of cells for currently known treatment 
from these privately banked samples, and also 
for their use in regenerative medicine. 
The coexistence of private and public banks in 
many countries has created a controversy, 
and is discussed in recent policy statements or 
opinions issued by professional 
organizations19 and other advisory groups.20 
Medical Rationale for Banking. These policies 
and opinions state that, in the current state of 
medical knowledge, the probability of 
autologous or familial use of umbilical cord 
blood stored at birth is very low, except for 
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particular situations, so that non-directed 
donations to public registries should be widely 
encouraged.21 The probability of developing a 
disease that will require an umbilical cord 
blood transplant is very low in the general 
population, so that it is currently highly unlikely 
for a family with no history of blood disease or 
metabolic disorder to ever need banked cord 
blood.22 In addition, if a genetic disease is 
present, cells from the patient's own cord 
blood cannot be used, as they will contain the 
disease-causing mutation. In some non-
genetic diseases such as leukemia, cells 
containing malignancy markers were found in 
the umbilical cord blood of the patient, making 
their use for treatment questionable. There 
have been isolated reports of successful 
treatment of leukemia and aplastic anemia 
with autologous cord blood transplantation,23 
but current medical opinion still weighs on the 
side of public banking of cord blood to ensure 
the availability of transplants to all who need 
them, rather than favour those who have the 
means to store blood but may be unable to 
use it. 
Representative Public Banks. HLA types are 
genetically determined, so that the probability 
of finding a matching donor is generally 
greater within one's racial or ethnic group. 
Thus, it is important for public cord blood 
banks to collect a sufficiently large number of 
samples from various racial and ethnic groups 
to ensure a good match for as many potential 
recipients as possible. It has been noted that 
patients from minority groups have difficulty 
finding a matching graft. As an example, in 
one bone marrow bank in the United States, 
African Americans had a 30% chance of 
finding a match while Caucasians had an 80% 
chance.24 An American study noted that cord 
blood banks did not initially achieve better 
representation of minorities in samples than 
bone marrow banks,25 although targeted 
interventions can improve this.26 This gap 
must be remedied for public banks to reach 
their full potential, and the importance of 
recruiting donors from minority groups is 
underlined in some policies.27 One study 
found that cord blood from certain ethnic 
groups may have lower cell count or an 
increased incidence of infectious disease,28 
suggesting a necessity to target these groups 
more effectively to permit collection of 
sufficient numbers of transplantation-suitable 
units. There is a need to build awareness 
about cord blood banking among members of 
such communities and to establish 
mechanisms to ensure that all populations 
have a fair opportunity to participate in cord 
blood banking and use.29 Generally, public 
banks restrict cord blood collection to a local 
network of hospitals, thus making it difficult for 
parents outside their target population to 
donate. One possible solution to increase the 
representation of minorities in cord blood 
banks is to expand the network of hospitals 
from which they collect donations to include 
those that serve minority groups, a strategy 
that has been used successfully in at least one 
case.30 Additional suggested measures to 
increase the representation of minorities in 
public cord banks include education as to the 
benefits of cord blood transplantation,31 
increasing the number of minority members 
hired as employees for the cord blood 
program, allowing donor recruitment during 
labour rather than requiring pre-natal 
recruitment, public service announcements, 
outreach through local community 
organizations and the distribution of 
educational materials in various languages.32 
In addition to increasing minority donor 
recruitment, most policies recommend that 
publicly-funded directed storage of cord blood 
be offered to families at risk of disorders that 
require transplantation, or which have a rare 
HLA type, to ensure equality of access to 
treatment.33 
Research Use of Unsuitable Samples. 
Collected umbilical cord blood may not be 
suitable for transplantation; the amount of cells 
in the cord blood may be insufficient, or the 
blood may test positive for an infectious or 
genetic disease. Indeed, about half of the cord 
blood units collected and intended for banking 
are not frozen for potential transplant use.34 A 
strong case exists for using these samples in 
research, and a recent position statement by a 
professional organization has been taken to 
task for largely ignoring this possibility and 
focusing too closely on current therapeutic 
uses of cord blood.35 It is interesting to note 
that the American and Canadian professional 
organizations surveyed here have also 
focused on current therapeutic use rather than 
research. The French CCNE, although 
approving of research, considered in 2002 that 
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the then-available sources of cord blood were 
adequate for research.36  
The promise of research should be taken into 
account when drafting consent forms and 
communicating with patients. One Quebec 
public cord bank, Héma-Québec, seeks 
consent to research use of cord blood 
unsuitable for transplantation at the same time 
as it obtains consent to donation. This 
approach has the merit of streamlining the 
consent process and potentially increasing the 
number of samples available for research. 
However, it requires that information be made 
available as to the type of research to be 
carried out with the donated cord blood, since 
parents may have objections to certain types 
of research. For instance, one study found that 
mothers polled six months after cord blood 
donation expressed concerns about genetic 
testing and research; with respect to research, 
there was discomfort about the possibility of 
use of donated umbilical cord blood being 
used for genetic manipulation or "cloning".37 
Thus, precise information about planned 
research use should be provided to patients. 
Parent Information and Consent. Given the 
current presence of two main types of players 
on the cord blood bank scene, it is important 
to consider whether and how parents obtain 
information about their options. Studies have 
shown that women are not well informed on 
these matters but want access to more and 
better information, and that pregnant women 
wish to be informed early enough in their 
pregnancy to have time to assimilate the 
information before making their decision.38 
Currently available sources of information 
appear patchy at best: because public banks 
usually only collect from a small number of 
hospitals, they may not disseminate 
information in other settings. Private banks 
may distribute materials in obstetrical clinics 
and practitioners' offices, but there is some 
concern about the objectivity of the information 
contained in these materials.39 Studies show 
that women would like health professionals to 
be available as a source of information.40 
However, if the clinic or practitioner is affiliated 
with a commercial bank, information obtained 
from that source may be suspect, and some 
policy statements explicitly require that 
affiliations and conflicts of interest should be 
clarified for the patient.41 
These studies also show that once informed, 
most women would consider donation to a 
public cord blood bank, although they have 
concerns about certain aspects of the 
process.42 
The lack of adequate information provided by 
a trusted source, as well as the difficulty of 
donating cord blood to a public bank when one 
is not available in the birthing hospital, often 
results in parents knowingly or unknowingly 
relinquishing all rights over their child’s cord 
blood and assuming that the hospital staff will 
dispose of it as it does other types of biological 
waste. It has been estimated that in 99 
percent of all deliveries the cord blood is 
discarded at the time of birth.43 This suggests 
that adequate information about cord blood 
banking options may increase the number of 
cord blood units collected for public use, 
providing hope for the recruitment of donors to 
expand public banks to reach their potential. 
Conclusion. Although umbilical cord blood 
banking raises many ethical and legal issues, 
the focus of this discussion has been the 
coexistence of public and private cord blood 
banks. The policy statements of professionals 
associations and advisory groups consulted so 
far all indicate that, based on the current state 
of medical evidence, childbearing women with 
no current or potential familial need of stem 
cell transplantation should be encouraged to 
donate cord blood to public cord blood banks. 
However, public registries must meet the goal 
of providing matches to as many as possible 
to justify the expense involved in creating and 
maintaining them. Because public banks 
require a great diversity of cells with HLA 
types from different populations so as to 
provide acceptable donors for as many as 
possible, it is important to encourage a wider 
collection base and create an information 
sharing network among cord blood banks to 
facilitate searches. Obtaining an increase in 
cord blood donations for public banks will 
require that reliable information be provided to 
childbearing women. In addition, to ensure fair 
access to healthcare services to all, families at 
risk of specific diseases treatable by cord 
blood transplantation should have the 
opportunity to store their child’s cord blood in a 
public registry for their exclusive use, as 
recommended by most of the policies 
surveyed.44 
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Given the emerging promise of cord blood 
stem cells, collected cord blood that does not 
meet standards for transplantation should be 
made available for research, and options 
should be provided to allow parents to choose 
the types of research they are willing to 
support. 
Public banks that meet these criteria should 
bring a common benefit justifying the 
investment. For this reason, results from a 
recent American initiative should be followed 
closely. The Stem Cell Therapeutic and 
Research Act of 2005,45 passed in December 
2005, aims to increase the inventory of cord 
blood samples in American public banks by 
150 000 units of high-quality cord blood. 
Approximately 79 million dollars have been 
allocated to this program through 2010. Cord 
blood banks participating in the program will 
have to comply with all federal quality 
standards and be accredited by an authority to 
be determined. A central system of match-
searching and reservation of units for 
transplant will be established. Measures will 
be implemented to favour donations from 
minority groups, so that members of 
underrepresented populations have the same 
probability of finding a match as other 
members of the population. Collected cord 
blood that is not appropriate for clinical use will 
be made available for peer-reviewed research. 
A pilot project is established to collect and 
store cord blood units from families where a 
first-degree relative has been diagnosed with 
a condition that will benefit from 
transplantation, at no cost to the family. This 
program is thus consistent with many of the 
recommendations contained in the EGE 
opinion, and its implementation should be a 
source of important data. 
Although most policy statements discourage 
private banking given the current state of 
medical knowledge, they are not usually in 
favour of prohibiting it.46 Some European 
countries have prohibited private banking on 
their territory (Italy, France and Spain), but 
private banking is considered to be increasing 
overall, and at a faster rate than public 
banking.47 Given this reality, mechanisms by 
which private banks may contribute to the 
common interest should be explored. 
Suggestions made to date include a 
contribution by private banks to the funding of 
public banks, public-private research 
collaborations or the donating cord to public 
banks of cord blood units that are no longer 
required. This last suggestion would be 
realizable only if all private cord blood units 
had been collected, tested and stored 
following standards applicable to public banks 
and Current Good Manufacturing Practice 
(CGMP) rules. 
Should advances in stem cell research provide 
evidence to support autologous banking of 
cord blood in the future, governing authorities 
would, in our opinion, need to consider the 
feasibility and costs associated with the 
systematic collection of cord blood from all 
newborns. This would solve the problem of 
supply and diversity and ensure fair access by 
all individuals to compatible cells, if not their 
own. This perspective is consistent with the 
opinion of the French CCNE on cord blood 
banking, which states that should autologous 
use of cord blood prove to be useful, the 
principles of justice and equity should 
predominate and autologous storage should 
not be a service left to commercial banks but 
become routine and underwritten by public 
authorities.48 The EGE's opinion concurs, 
stating that if the use of one's own cord blood 
cells becomes of value in the future, "storage 
should not be a service left to commercial 
banks but should be taken over by the public 
sector in order to ensure fair access to 
healthcare services for everybody."49 
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